253 related articles for article (PubMed ID: 23509284)
1. Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer.
Knight JF; Lesurf R; Zhao H; Pinnaduwage D; Davis RR; Saleh SM; Zuo D; Naujokas MA; Chughtai N; Herschkowitz JI; Prat A; Mulligan AM; Muller WJ; Cardiff RD; Gregg JP; Andrulis IL; Hallett MT; Park M
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):E1301-10. PubMed ID: 23509284
[TBL] [Abstract][Full Text] [Related]
2. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
3. Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer.
Zhang S; Chung WC; Miele L; Xu K
Cancer Biol Ther; 2014 May; 15(5):633-42. PubMed ID: 24556651
[TBL] [Abstract][Full Text] [Related]
4. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.
Pfefferle AD; Agrawal YN; Koboldt DC; Kanchi KL; Herschkowitz JI; Mardis ER; Rosen JM; Perou CM
Dis Model Mech; 2016 Jul; 9(7):749-57. PubMed ID: 27149990
[TBL] [Abstract][Full Text] [Related]
5. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
[TBL] [Abstract][Full Text] [Related]
6. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells.
Herschkowitz JI; Zhao W; Zhang M; Usary J; Murrow G; Edwards D; Knezevic J; Greene SB; Darr D; Troester MA; Hilsenbeck SG; Medina D; Perou CM; Rosen JM
Proc Natl Acad Sci U S A; 2012 Feb; 109(8):2778-83. PubMed ID: 21633010
[TBL] [Abstract][Full Text] [Related]
7. p53 controls the plasticity of mammary luminal progenitor cells downstream of Met signaling.
Chiche A; Di-Cicco A; Sesma-Sanz L; Bresson L; de la Grange P; Glukhova MA; Faraldo MM; Deugnier MA
Breast Cancer Res; 2019 Jan; 21(1):13. PubMed ID: 30683141
[TBL] [Abstract][Full Text] [Related]
8. Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas.
O'Leary KA; Rugowski DE; Sullivan R; Schuler LA
Oncogene; 2014 Jun; 33(23):3075-82. PubMed ID: 23873024
[TBL] [Abstract][Full Text] [Related]
9. Lunatic Fringe and p53 Cooperatively Suppress Mesenchymal Stem-Like Breast Cancer.
Chung WC; Zhang S; Challagundla L; Zhou Y; Xu K
Neoplasia; 2017 Nov; 19(11):885-895. PubMed ID: 28938159
[TBL] [Abstract][Full Text] [Related]
10. p53 deficiency induces cancer stem cell pool expansion in a mouse model of triple-negative breast tumors.
Chiche A; Moumen M; Romagnoli M; Petit V; Lasla H; Jézéquel P; de la Grange P; Jonkers J; Deugnier MA; Glukhova MA; Faraldo MM
Oncogene; 2017 Apr; 36(17):2355-2365. PubMed ID: 27775073
[TBL] [Abstract][Full Text] [Related]
11. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer.
Xu K; Usary J; Kousis PC; Prat A; Wang DY; Adams JR; Wang W; Loch AJ; Deng T; Zhao W; Cardiff RD; Yoon K; Gaiano N; Ling V; Beyene J; Zacksenhaus E; Gridley T; Leong WL; Guidos CJ; Perou CM; Egan SE
Cancer Cell; 2012 May; 21(5):626-641. PubMed ID: 22624713
[TBL] [Abstract][Full Text] [Related]
12. Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.
Cicchini M; Chakrabarti R; Kongara S; Price S; Nahar R; Lozy F; Zhong H; Vazquez A; Kang Y; Karantza V
Autophagy; 2014; 10(11):2036-52. PubMed ID: 25483966
[TBL] [Abstract][Full Text] [Related]
13. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer.
Ponzo MG; Lesurf R; Petkiewicz S; O'Malley FP; Pinnaduwage D; Andrulis IL; Bull SB; Chughtai N; Zuo D; Souleimanova M; Germain D; Omeroglu A; Cardiff RD; Hallett M; Park M
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12903-8. PubMed ID: 19617568
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
Prat A; Parker JS; Karginova O; Fan C; Livasy C; Herschkowitz JI; He X; Perou CM
Breast Cancer Res; 2010; 12(5):R68. PubMed ID: 20813035
[TBL] [Abstract][Full Text] [Related]
15. Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature.
Franks SE; Campbell CI; Barnett EF; Siwicky MD; Livingstone J; Cory S; Moorehead RA
Oncogene; 2012 Jul; 31(27):3298-309. PubMed ID: 22020329
[TBL] [Abstract][Full Text] [Related]
16. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.
Tang YH; Rockstroh A; Sokolowski KA; Lynam LR; Lehman M; Thompson EW; Gregory PA; Nelson CC; Volpert M; Hollier BG
Breast Cancer Res; 2022 Jan; 24(1):8. PubMed ID: 35078508
[TBL] [Abstract][Full Text] [Related]
17. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
18. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas.
Gerhard R; Ricardo S; Albergaria A; Gomes M; Silva AR; Logullo ÂF; Cameselle-Teijeiro JF; Paredes J; Schmitt F
Breast; 2012 Jun; 21(3):354-60. PubMed ID: 22464177
[TBL] [Abstract][Full Text] [Related]
20. Frequent met oncogene amplification in a Brca1/Trp53 mouse model of mammary tumorigenesis.
Smolen GA; Muir B; Mohapatra G; Barmettler A; Kim WJ; Rivera MN; Haserlat SM; Okimoto RA; Kwak E; Dahiya S; Garber JE; Bell DW; Sgroi DC; Chin L; Deng CX; Haber DA
Cancer Res; 2006 Apr; 66(7):3452-5. PubMed ID: 16585167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
